## JC17 Rec'd PCT/PTO 15 JUL 2005

## **Amendments to the Claims**

1. (Original) A compound having a structural Formula I,

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is:  $O, S \text{ or } NR^{14};$ 

$$Y \longrightarrow Q$$
 $P4 \quad P5$ 

W is:

, hydrogen,  $C_1$ - $C_6$  alkyl,  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl, haloalkyl or acyl;

Q is:  $-C(O)OR^6$  or  $R^{6A}$ ;

X is: a bond, C, O, S or  $S[O]_p$ ;

Y is: a bond, S, C or O;

- Z is: a) aliphatic group,
  - b) aryl,
  - c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
  - d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

- e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
- f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

```
m and n' are each independently: 0, 1, 2, 3 or 4;
         0, 1, 2 or 3;
n is:
         1 or 2;
p is:
r is:
         1, 2, 3 or 4;
v is:
         1 or 2;
R<sup>1</sup> is: hydrogen, wherein when Z is phenyl or naphthyl and R<sup>2</sup> is H, R<sup>1</sup> is not H,
         haloalkyl,
         C_1-C_6 alkyl,
         C_1-C_6 alkyl-C_1-C_6 alkoxy,
         C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
         C<sub>2</sub>-C<sub>6</sub> alkenyl,
         C<sub>2</sub>-C<sub>6</sub> alkynyl,
         (CH_2)_{n'}C_3-C_6 cycloalkyl,
         C_1-C_6 alkoxy,
         aryl, or
         R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
         wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
         substituted with one or more groups independently selected from R<sup>15</sup>;
```

R<sup>1a</sup> and R<sup>1b</sup> are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

```
R<sup>2</sup> is: hydrogen,
          haloalkyl,
          C_1-C_6 alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C2-C6 alkenyl,
          C<sub>2</sub>-C<sub>6</sub> alkynyl,
          (CH_2)_{n'}C_3-C_6 cycloalkyl,
          C_1-C_6 alkoxy,
          aryl, or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
          substituted with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-
          membered ring; and wherein alkyl being optionally substituted with one or more
          groups independently selected from R<sup>15</sup>;
R<sup>3</sup> is: hydrogen,
          halo,
          cyano,
          haloalkyl,
          C_1-C_6 alkyl,
          (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted
                    with oxo,
          (C_1-C_4 \text{ alkyl})-NR^7C(O)_nR^9, and
          wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or
          more groups independently selected from R<sup>15</sup>;
R<sup>4</sup> and R<sup>5</sup> are each independently:
          hydrogen,
          halo,
```

 $C_1$ - $C_6$  alkyl  $C_1$ - $C_6$  alkoxy; aryloxy;  $N(R^8)_2$ ,  $SR^8$  or  $R^4$  and  $R^5$  together being a 3- to 8-membered ring;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>6A</sup> is: carboxamide, C<sub>1</sub>-C<sub>3</sub> alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R<sup>7</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently:

hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

R<sup>14</sup> is: hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>1</sub>-C<sub>6</sub> alkyl-COOR<sup>6</sup>, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>; and

R<sup>15</sup> is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl, N(R<sup>8</sup>)<sub>2</sub>, NR<sup>8</sup>S(O)<sub>2</sub>R<sup>9</sup>, NR<sup>8</sup>C(O)<sub>p</sub>R<sup>9</sup>, C(O)NR<sup>8</sup>R<sup>9</sup>, C(O)<sub>p</sub>R<sup>8</sup>, SR<sup>8</sup>, S(O)<sub>p</sub>R<sup>8</sup> or S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>.

- 2. (Original) The compound Claim 1, wherein X and Y are respectively S and O; S and C; or C and O.
- 3. (Original) The compound of Claim 2, wherein Z is  $C_1$ - $C_6$  alkyl, aryl or heteroaryl.

- 4. (Original) The compound of Claim 3, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.
- 5. (Original) The compound of Claim 4, wherein  $R^1$  is  $C_3$ - $C_6$  alkyl or  $(CH_2)_n$ : $C_3$ - $C_6$  cycloalkyl;  $R^2$  and  $R^3$  are each independently  $C_1$ - $C_3$  alkyl; and r is 1.
- 6. (Original) The compound Claim 5, wherein X is positioned para to Y; and R<sup>3</sup> is positioned ortho to Y.
  - 7. (Original) A compound having a structural Formula II,

$$Z \longrightarrow (CH_2)_m \longrightarrow S \longrightarrow N \longrightarrow [C]_n \longrightarrow R^{1a} \times X \longrightarrow R^{2a} \times (R^3)_r \times R^4 \times R^5$$

$$II$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

Q is: 
$$-C(O)OR^6$$
 or  $R^{6A}$ ;

X is: a bond, C, O, S or 
$$S[O]_p$$
;

- Z is: a) aliphatic group,
  - b) aryl,
  - c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
  - d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

- e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
- f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

```
m and n' are each independently: 0, 1, 2, 3 or 4;
         0, 1, 2 or 3;
n is:
p is:
          1 or 2;
r is:
         1, 2, 3 or 4;
R<sup>1</sup> is: aryl,
         haloalkyl,
         C_1-C_6 alkyl,
         C_1-C_6 alkyl-C_1-C_6 alkoxy,
         C_1-C_6 alkyl-aryl,
         C<sub>2</sub>-C<sub>6</sub> alkenyl,
         C<sub>2</sub>-C<sub>6</sub> alkynyl,
         (CH_2)_{n'}C_3-C_6 cycloalkyl,
         C<sub>1</sub>-C<sub>6</sub> alkoxy or
         R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
         wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
         substituted with one or more groups independently selected from R<sup>15</sup>;
```

 $R^{1a}$  and  $R^{1b}$  are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

R<sup>2</sup> is: hydrogen, haloalkyl,

 $C_1$ - $C_6$  alkoxy;

```
C_1-C_6 alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C<sub>2</sub>-C<sub>6</sub> alkenyl,
          C2-C6 alkynyl,
          (CH_2)_{n'}C_3-C_6 cycloalkyl,
          C_1-C_6 alkoxy,
          aryl, or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
          substituted with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-
          membered ring; and wherein alkyl being optionally substituted with one or more
          groups independently selected from R<sup>15</sup>:
R<sup>3</sup> is: hydrogen,
          halo,
          cyano,
          haloalkyl,
          C_1-C_6 alkyl,
          (CH_2)_{n'}C_3-C_6 cycloalkyl,
          (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted
                   with oxo,
         (C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9, and
          wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or
          more groups independently selected from R<sup>15</sup>;
R<sup>4</sup> and R<sup>5</sup> are each independently:
         hydrogen,
         halo,
         C<sub>1</sub>-C<sub>6</sub> alkyl
```

aryloxy;

 $N(R^8)_{2}$ 

SR<sup>8</sup> or

R<sup>4</sup> and R<sup>5</sup> together being a 3- to 8-membered ring;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>6A</sup> is: carboxamide, C<sub>1</sub>-C<sub>3</sub> alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R<sup>7</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently:

hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

- $R^{15}$  is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  $N(R^8)_2$ ,  $NR^8S(O)_2R^9$ ,  $NR^8C(O)_pR^9$ ,  $C(O)NR^8R^9$ ,  $C(O)_pR^8$ ,  $SR^8$ ,  $S(O)_pR^8$  or  $S(O)_2NR^8R^9$ .
- 8. (Original) The compound of Claim 7, wherein X and Y are respectively S and O; S and C; or C and O.
- 9. (Original) The compound of Claim 8, wherein Z is  $C_1$ - $C_6$  alkyl, aryl or heteroaryl.
- 10. (Original) The compound of Claim 9, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

- 11. (Original) The compound of Claim 10, wherein  $R^1$  is  $C_3$ - $C_6$  alkyl or  $(CH_2)_n \cdot C_3$ - $C_6$  cycloalkyl;  $R^2$  and  $R^3$  are each independently  $C_1$ - $C_3$  alkyl; and r is 1.
- 12. (Original) The compound Claim 11, wherein X is positioned para to Y; and R<sup>3</sup> is positioned ortho to Y.
- 13. (Original) The compound of Claim 7, wherein the compound having a structural Formula III,

$$Z \xrightarrow{\underset{O}{\overset{|}{\text{II}}}} \underset{R^1 \overset{|}{\overset{|}{\text{R}}} \overset{|}{\text{III}}}{\overset{|}{\text{OH}}} X \xrightarrow{\underset{(R^3)_r}{\overset{|}{\text{OH}}}} \overset{O}{\underset{R^4 \overset{|}{\text{R}}}{\text{OH}}}$$

n is: 1 or 2;

r is: 1, 2, 3, or 4;

X is: S or C;

Y is: C or O;

Z is: aryl or a 5- to 10-membered heteroaryl,

wherein aryl and heteroaryl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

 $R^1$  and  $R^2$  are each independently:  $C_1$ - $C_6$  alkyl or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl; and  $R^{1a}$  and  $R^{1b}$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each independently: hydrogen or  $C_1$ - $C_6$  alkyl.

14. (Original) The compound of Claim 13, wherein the compound having a structural Formula IV,

$$(R^{12})_{q} \longrightarrow 0$$

$$0$$

$$0$$

$$R^{1a}$$

$$0$$

$$R^{1}$$

$$R^{1b}$$

$$R^{2}$$

$$IV$$

q is 1, 2, 3, 4, or 5;

R<sup>8</sup> and R<sup>9</sup> are each independently:

hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, or heterocyclyl,

wherein alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy; and;

R<sup>12</sup> is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryl, heteroaryl, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl, N(R<sup>8</sup>)<sub>2</sub>, NR<sup>8</sup>S(O)<sub>2</sub>R<sup>9</sup>, NR<sup>8</sup>C(O)<sub>n</sub>R<sup>9</sup>, C(O)NR<sup>8</sup>R<sup>9</sup>, C(O)<sub>n</sub>R<sup>8</sup>, SR<sup>8</sup>, S(O)<sub>n</sub>R<sup>8</sup> or S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>.

15. (Original) The compound of Claim 14, wherein the compound having a structural Formula V,

$$(R^{12})_1 \xrightarrow{(R^{12})_2} S \xrightarrow{R^3} O \xrightarrow{CO_2H} V$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein  $R^1$  and  $R^2$  are each independently  $C_1$ - $C_4$  alky or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl;  $R^3$  is  $C_1$ - $C_4$  alky;  $(R^{12})_1$  is halo, haloalkyl, or haloalkyloxy; and  $(R^{12})_2$  is F, Cl or Br.

- 16. (Original) The compound of Claim 15, wherein R<sup>1</sup> is methyl, ethyl, propyl, clcylopropyl, cycloproylmethyl, cyclobutyl; R<sup>3</sup> is methyl and (R<sup>12</sup>)<sub>1</sub> is OCF<sub>3</sub>.
  - 17. (Original) A compound having a structural Formula VI,

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein: X is: a bond, C, O, S or  $S[O]_p$ ;

Y is: a bond, S, C or O;

Z is: heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S, and wherein heteroaryl being optionally substituted with one or more groups selected from R<sup>15</sup>;

n is: 0, 1, 2 or 3;

n' is: 0, 1, 2, 3 or 4;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

R<sup>1</sup> is: hydrogen,

haloalkyl,

 $C_1$ - $C_6$  alkyl,

 $C_1$ - $C_6$  alkyl- $C_1$ - $C_6$  alkoxy,

 $C_1$ - $C_6$  alkyl-aryl,

C2-C6 alkenyl,

C2-C6 alkynyl,

 $(CH_2)_{n'}C_3-C_6$  cycloalkyl,

 $C_1$ - $C_6$  alkoxy, aryl, or

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

 $R^{1a}$  and  $R^{1b}$  are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

R<sup>2</sup> is: hydrogen,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

 $C_1$ - $C_6$  alkyl- $C_1$ - $C_6$  alkoxy,

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl,

 $(CH_2)_{n'}C_3-C_6$  cycloalkyl,

 $C_1$ - $C_6$  alkoxy,

aryl, or

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

 $R^{2a}$  is: hydrogen, halo or  $C_1$ - $C_6$  alkyl and wherein  $R^2$  and  $R^{2a}$  together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from  $R^{15}$ ;

R<sup>3</sup> is: hydrogen, halo,

cyano,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

 $(CH_2)_{n'}C_3-C_6$  cycloalkyl,

 $(C_1-C_4 \text{ alkyl})$ -heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,

 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$ , and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>7</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently:

hydrogen,  $C_1$ - $C_6$  alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy; and

 $R^{15}$  is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $N(R^8)_2$ ,  $NR^8S(O)_2R^9$ ,  $NR^8C(O)_pR^9$ ,  $C(O)NR^8R^9$ ,  $C(O)_pR^8$ ,  $SR^8$ ,  $S(O)_pR^8$  or  $S(O)_2NR^8R^9$ .

18. (Original) The compound of Claim17, wherein the compound having a structural Formula VII,

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 5 \\ 6 \end{array} \end{array} \xrightarrow{\begin{array}{c} 4 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} 1 \\ 7 \end{array}$$

q is: 1, 2, 3, or 4;

T is: O, NR<sup>1c</sup> or S;

R<sup>1c</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>10</sup> and R<sup>11</sup> are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,

 $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy; and

wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>.

19. (Original) The compound of Claim 18, wherein the compound having a structural Formula VIII,

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 5 \\ 6 \end{array} \end{array} \xrightarrow{\begin{array}{c} 4 \\ 5 \end{array} \xrightarrow{\begin{array}{c} 7 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} 8 \\ 7 \end{array} \xrightarrow{\begin{array}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

 $R^1$  is:  $C_3$ - $C_5$  alky or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently: C<sub>1</sub>-C<sub>3</sub> alkyl;

 $R^{10}$  is: halo, haloalkyl or  $C_1$ - $C_3$  alkyl, and

wherein R<sup>10</sup> being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

R<sup>11</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl.

- 20. (Original) The compound of Claim 19, wherein R<sup>10</sup> is Cl, F, Br, CH<sub>3</sub> or CF<sub>3</sub> being substituted at a position 5 of benzothiophenyl ring.
  - 21. (Original) A compound having a structural Formula IX,

$$Z = (CH_2)_m - S = N - [C]_n - [C]_n - [R^{1a}]_{R^{1b}} - [R^{2a}]_{r} - [R^{3}]_{r}$$

$$IX$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is:  $O, S \text{ or } NR^{14};$ 

$$Y \longrightarrow Q$$

W is:

 $R^4$   $R^5$  , hydrogen,  $C_1$ - $C_6$  alkyl,  $(CH_2)_{n'}C_3$ - $C_6$  cycloalkyl, haloalkyl or acyl;

Q is:  $-C(O)OR^6$  or  $R^{6A}$ ;

X is: a bond, C, O, S or  $S[O]_p$ ;

Y is: a bond, S, C or O;

- Z is: a) aliphatic group,
  - b) aryl,
  - c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
  - d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

- e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
- f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

```
m and n' are each independently: 0, 1, 2, 3 or 4;
n is:
         0, 1, 2 or 3;
         1 or 2;
p is:
r is:
         1, 2, 3 or 4;
v is:
         1 or 2;
R<sup>1</sup> is: hydrogen,
         haloalkyl,
         C_1-C_6 alkyl,
         C_1-C_6 alkyl-C_1-C_6 alkoxy,
         C_1-C_6 alkyl-aryl,
         C<sub>2</sub>-C<sub>6</sub> alkenyl,
         C<sub>2</sub>-C<sub>6</sub> alkynyl,
         (CH_2)_{n'}C_3-C_6 cycloalkyl,
         C_1-C_6 alkoxy,
         aryl, or
         R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
         wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
         substituted with one or more groups independently selected from R<sup>15</sup>;
```

R<sup>1a</sup> and R<sup>1b</sup> are each independently:

```
hydrogen,
```

 $C_1$ - $C_6$  alkyl, or

 $R^{1}$  and  $R^{1a}$ ,  $R^{1}$  and  $R^{1b}$ ,  $R^{2}$  and  $R^{1a}$ ,  $R^{2}$  and  $R^{1b}$  or  $R^{1a}$  and  $R^{1b}$  together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of  $R^{1a}$  and  $R^{1b}$  is not hydrogen;

R<sup>2</sup> is: hydrogen,

```
haloalkyl,
          C_1-C_6 alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C<sub>2</sub>-C<sub>6</sub> alkenyl,
          C<sub>2</sub>-C<sub>6</sub> alkynyl,
          (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          C_1-C_6 alkoxy,
          aryl, or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
          substituted with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-
          membered ring; and wherein alkyl being optionally substituted with one or more
          groups independently selected from R<sup>15</sup>;
R<sup>3</sup> is: hydrogen,
          halo,
          cyano,
          haloalkyl,
          C_1–C_6 alkyl,
          (CH_2)_{n'}C_3-C_6 cycloalkyl,
          (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted
                    with oxo,
         (C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9, and
          wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or
          more groups independently selected from R<sup>15</sup>;
R<sup>4</sup> and R<sup>5</sup> are each independently:
          hydrogen,
          halo,
          C<sub>1</sub>-C<sub>6</sub> alkyl
```

 $C_1$ - $C_6$  alkoxy;

aryloxy;

 $N(R^8)_2$ ,

SR<sup>8</sup> or

R<sup>4</sup> and R<sup>5</sup> together being a 3- to 8-membered ring;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>6A</sup> is: carboxamide, C<sub>1</sub>-C<sub>3</sub> .alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

 $R^7$  is: hydrogen or  $C_1$ - $C_6$  alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently:

hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

R<sup>14</sup> is: hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>1</sub>-C<sub>6</sub> alkyl-COOR<sup>6</sup>, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>; and

 $R^{15} \text{ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, $(CH_2)_n$\cdot$C_3$-$C_6$ cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, $SR^8$, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.}$ 

22. (Original) The compound of Claim 21, wherein the compound having a structural Formula X:

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 4 \\ \\ \\ \\ \\ \\ \end{array}} \xrightarrow{R^{11}} O \xrightarrow[]{R^{1a}} X \xrightarrow{P} X \xrightarrow{COOR^{6}} R^{10}$$

$$R^{1a} \times X \xrightarrow{R^{1a}} X \xrightarrow{R^{1a}} R^{1a} \times R^{2}$$

$$R^{10} \times R^{10} \times R^{10} \times R^{10}$$

$$X \times R^{10} \times R^{10} \times R^{10}$$

n and q are each independently: 1, 2, 3 or 4;

T is: O, NR<sup>1c</sup> or S;

X is: C, O or S;

 $R^1$  is: hydrogen,  $C_1$ - $C_6$  alkyl or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl;

 $R^{1a}$ ,  $R^{1b}$ ,  $R^{1c}$  and  $R^2$  are each independently: hydrogen or  $C_1$ - $C_6$  alkyl; and

R<sup>10</sup> and R<sup>11</sup> are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,

 $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from  $R^{15}$ .

23. (Original) The compound of Claim 22, wherein the compound having a structural Formula XI:

$$(R^{10})_{q} \xrightarrow{5} \overset{4}{\overset{4}{\overset{}}} \overset{3}{\overset{0}{\overset{}}} \overset{0}{\overset{11}{\overset{}}} - N \overset{R^{1}}{\overset{}} \overset{R^{2}}{\overset{}} \overset{R^{2}}{\overset{}} \overset{R^{1}}{\overset{}} \overset{R^{2}}{\overset{}} \overset{R^{1}}{\overset{}} \overset{R^{2}}{\overset{}} \overset{R}{\overset{}} \overset{R}{\overset{}} \overset{R}{\overset{}}} \overset{R}{\overset{}} \overset{R}{\overset{}} \overset{R}{\overset{}}} \overset{R}{\overset{R}}{\overset{}} \overset{R}{\overset{}} \overset{R}{\overset{}}} \overset{R}{\overset{}} \overset{R}{\overset{}}} \overset{R}{\overset{}} \overset{R}{\overset{}} \overset{R}{\overset{}}} \overset{R}{\overset{}} \overset{R}{\overset{}}} \overset{R}{\overset{}}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein: q is 1 or 2;

E is O, S or  $NR^{14}$ ;

 $R^1$ ,  $R^2$  and  $R^{11}$  are each independently:  $C_1$ - $C_4$  alkyl;

R<sup>10</sup> is: Cl, F, Br, CH<sub>3</sub> or CF<sub>3</sub>, and wherein R<sup>10</sup> being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

R<sup>14</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aryl.

24. (Original) A compound selected from the group consisting of No. 1-120 and 121:

No.	Structure	Name
1	F, , , O	3-(4-{2-[(5-Fluoro-3-
		methyl-
		benzo[b]thiophene-2-
	's 's 'N 's '	sulfonyl)-propyl-
	őö	amino]-ethylsulfanyl}-
		2-methyl-phenyl)-
		propionic acid
2	CI	3-(4-{2-[(5-Chloro-3-
		methyl-
	OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
		2-methyl-phenyl)-
		propionic acid
3	CI	(4-{2-[(5-Chloro-3-
İ		methyl-benzofuran-2-
	OH C	sulfonyl)-propyl-
		amino]-1-methyl-
		ethoxy}-2-methyl-
		phenoxy)-acetic acid
4	CI	(4-{2-[(5-Chloro-3-
		methyl-benzofuran-2-
	OH C	sulfonyl)-propyl-
ŀ		amino]-1-methyl-
	o´ò	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid
5	CI	3-(4-{2-[(5-Chloro-3-
1		methyl-
	HO, CH	benzo[b]thiophene-2-
	`s`s\	sulfonyl)-propyl-
	σ´ο ·	amino]-1-methyl-
		ethylsulfanyl}-2-
		methyl-phenyl)-
<u> </u>	Cl	propionic acid
6	CIO	(4-{2-[(5-Chloro-3-
		ethyl-
	THO YEAR	benzo[b]thiophene-2-
	`s s s	sulfonyl)-propyl-
	ő o	amino]-1-methyl-
		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid

7		4-{2-[(6-Chloro-3- methyl-
	CI OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
8		4-{2-[(7-Chloro-3-
	OH CONTRACTOR	methyl-
		benzo[b]thiophene-2-
	CI S S,S, N S	sulfonyl)-propyl-
	0 0	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
9	,CI	(4-{2-[(4-Chloro-3-
		methyl-
	OH ON	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	S S	amino]-ethylsulfanyl}-
	0 0	2-methyl-phenoxy)-
1		acetic acid
10	Cl F	(4-{2-[(5-Chloro-3-
10		
	F O O	trifluoromethyl-
	OH OH	benzo[b]thiophene-2-
	's s s s	sulfonyl)-propyl-
	0 0	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
11	0.5	acetic acid
11	CI CF <sub>3</sub> O	(4-{2-[(5-Chloro-3-
	S-N.	trifluoromethyl-
	s b o o	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	0	amino]-1-methyl-
		ethoxy}-2-methyl-
		phenoxy)-acetic acid
12	Q	2-[4-(3-{[5-(4'-Fluoro-
	TO T	biphenyl-4-yl)-
		thiophene-2-sulfonyl]-
		propyl-amino}-propyl)-
		phenoxy]-2-methyl-
		propionic acid
13	/	2-(4-{2-[(5-Chloro-3-
	o <	methyl-
	s , s , . ;	benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethyl}-
	CI OH OH	phenoxy)-2-methyl-
	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	
		propionic acid

14	OH OH	2-(4-{3-[(3,5-Dimethylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
15	F O N OH	2-(4-{3-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
16	CI, SI, NOH	2-(4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(2,2,2-trifluoro-ethyl)-amino]-propyl}-phenoxy)-2-methyl-propionic acid
17	SON	2-(4-{2-[(3-Ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-3-propyl-phenoxy)-2-methyl-propionic acid
18	CI S O O O O O O O O O O O O O O O O O O O	2-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
19	CI S S N	3-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid

20	F SOO O'S'N S	[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
21	CI S S N S	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-aceticacid
22	CI S O OH	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-aceticacid
23		(2-Methyl-4-{2-[(6-phenoxy-pyridine-3-sulfonyl)-propyl-amino]-ethylsulfanyl} phenoxy)-acetic acid
24	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH	(2-Methyl-4-{2-[(5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
25	NO CH <sub>3</sub>	(2-Methyl-4-{2-[(4-oxazol-5-yl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
26	O S CH <sub>3</sub> O CH <sub>3</sub> O O O O O	(2-Methyl-4-{2-[propyl- (4-pyrazol-1-yl- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid

27	CH <sub>3</sub>	(2-Methyl-4-{2-[(2-naphthalen-1-yl-ethanesulfonyl)-propylamino]-ethylsulfanyl}-phenoxy)-acetic acid
28	F F O CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	(2-Methyl-4-{2-[propyl- (4- trifluoromethylphenylm ethanesulfonyl)-amino]- ethylsulfanyl}- phenoxy)-acetic acid
29	O S S N CH <sub>3</sub> O O O O O O O O O	(4-{2-[(Biphenyl-3-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
30	O CH <sub>3</sub> CH <sub>3</sub> OH	(4-{2-[(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
31	H <sub>3</sub> C S N S CH <sub>3</sub> OH	[2-Methyl-4-(2-{[5-(2-methylsulfanyl-pyrimidin-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
32	F H <sub>3</sub> C CH <sub>3</sub>	[2-Methyl-4-(2-{[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
33	F F S O CH <sub>3</sub> O CH <sub>4</sub>	[2-Methyl-4-(2-{[5-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid

34	_ F CH <sub>3</sub> chiral	(D) (2 Mathed 4 (1
34	F	(R)-(2-Methyl-4-{1- methyl-2-[(3-methyl-5-
		trifluoromethyl-
	S O CH <sub>3</sub>	benzo[b]thiophene-2-
	CH <sub>3</sub> OH	sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
35	CH <sub>2</sub> chiral	phenoxy)-acetic acid
33	I 3 .	(R)-3-(4-{2-[(6-Chloro-
	F S N CH <sub>3</sub>	5-fluoro-3-methyl-
	CI S O CH <sub>3</sub>	benzo[b]thiophene-2-
	CI CH <sub>3</sub> CH <sub>3</sub>	sulfonyl)-propyl-
	Ċн <sub>а</sub> он	amino]-1-methyl-
		ethylsulfanyl}-2-
		methyl-phenyl)-
26	CII.	propionic acid
36	CH <sub>3</sub> chiral	(R)-(4-{2-[(6-Chloro-5-
}	S CH <sub>3</sub>	fluoro-3-methyl-
1	F S CH <sub>3</sub> CI CH <sub>3</sub> CO CH <sub>3</sub> CO CH <sub>3</sub> CO CH <sub>3</sub> CO C	benzo[b]thiophene-2-
		sulfonyl)-propyl-
-	Сн <sub>з</sub> Он	amino]-1-methyl-
	-	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
27	0	acid
37	0 0	(4-{2-[(4-Bromo-
	S CH <sub>3</sub>	benzenesulfonyl)-
		propyl-amino]-
	Br O	ethylsulfanyl}-2-
	Ċн <sub>з</sub> Он	methyl-phenoxy)-acetic acid
38	0	(4-{2-[(3,4-Dichloro-
36		benzenesulfonyl)-
	O' NO SALAN SA	propyl-amino]-
		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
	ĊН <sub>3</sub> ОН	acid
39	Q	(4-{2-[(4-Isopropyl-
	O II S CH <sub>3</sub>	benzenesulfonyl)-
		propyl-amino]-
	H <sub>3</sub> C	ethylsulfanyl}-2-
	CH <sub>3</sub> CH <sub>3</sub> OH	methyl-phenoxy)-acetic
	CH <sub>3</sub> CH <sub>3</sub> OH	acid
10	0	
40	O II S CH <sub>3</sub>	(2-Methyl-4-{2-[(4-
		pentyl-
	H <sub>3</sub> C	benzenesulfonyl)-
	CH <sub>3</sub> OH	propyl-amino]-
		ethylsulfanyl}-
		phenoxy)-acetic acid

42	FF ON S CH3  CH3  CH3  CH3  CH3  CH3  CH3	(4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid (2-Methyl-4-{2-[propyl-(3-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
43	CH <sub>3</sub> O CH <sub>3</sub> CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	(4-{2-[(4-Bromo-2-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
44	Br CH <sub>3</sub> CH <sub>3</sub> OH	(4-{2-[(3,4-Dibromobenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid
45	H <sub>3</sub> C OH <sub>3</sub> OH	(2-Methyl-4-{2-[propyl- (4-propyl- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
46	CI O S CH <sub>3</sub> CH <sub>3</sub>	(4-{2-[(2,4-Dichloro- benzenesulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
47	CH <sub>3</sub> CH <sub>3</sub>	(4-{2-[(4-Iodo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid

48	. 0	(4-{2-[(3-Chloro-4-
.0	O O II CI S CH₃	methyl-
İ		benzenesulfonyl)-
	H <sub>3</sub> C O	propyl-amino]-
	CH <sub>3</sub> OH	ethylsulfanyl}-2-
	5113	methyl-phenoxy)-acetic
		acid
49	F O	(4-{2-[(4-Bromo-2,5-
	S CH <sub>3</sub>	difluoro-
		benzenesulfonyl)-
	Br	propyl-amino]-
Ì	F CH <sub>3</sub> OH	ethylsulfanyl}-2-
	3	methyl-phenoxy)-acetic
50	O chiral	acid
50	l o. ii	(2-Methyl-4-{1-methyl-
		2-[propyl-(4- trifluoromethyl-
	F CH <sub>3</sub>	benzenesulfonyl)-
1		amino]-ethylsulfanyl}-
	Ė ĊН₃ О́Н	phenoxy)-acetic acid
51	chiral	(4-{2-[(3,4-Dichloro-
	0	benzenesulfonyl)-
		propyl-amino]-1-
	CH <sub>3</sub>	methyl-ethylsulfanyl}-
	CI CI	2-methyl-phenoxy)-
	сн <sub>з</sub> о́н	acetic acid
52	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(2-Methyl-4-{2-[propyl-
		(2'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
		amino]-ethylsulfanyl}-
	ĊH₃ ÓH	phenoxy)-acetic acid
53	0 0	(2-Methyl-4-{2-[propyl-
	F E CH <sub>3</sub>	(3'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
	F CH. OH	amino]-ethylsulfanyl}-
	•	phenoxy)-acetic acid
54	0	(2-Methyl-4-{2-[propyl-
	S N CH <sub>3</sub>	(4'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
	F CH <sub>3</sub> OH	amino]-ethylsulfanyl}-
	i i i	phenoxy)-acetic acid
55	0	(4-{2-{(2'-Fluoro-
33	O II S CH <sub>3</sub>	biphenyl-4-sulfonyl)-
1	/ \\ / * \\ / * \ / \\ / * \	(ועווטוועוד
}		propyl-aminol-
		propyl-amino]- ethylsulfanyl}-2-
		ethylsulfanyl}-2-
	CH <sub>3</sub>	

56	0   CH <sub>3</sub>	(4-{2-[(4'-Fluoro-biphenyl-4-sulfonyl)-
		propyl-amino]-
	CH₃ OH	ethylsulfanyl}-2- methyl-phenoxy)-acetic
57	0 0 0 0	acid (2-Methyl-4-{2-[propyl-
	S N CH,	(4'-trifluoromethoxy-
	CH <sub>3</sub>	biphenyl-4-sulfonyl)- amino]-ethylsulfanyl}-
58	F TO S	phenoxy)-acetic acid
38	O II S CH <sub>3</sub>	(4-{2-[(3',4'-Dichloro-biphenyl-4-sulfonyl)-
		propyl-amino]- ethylsulfanyl}-2-
	СІ СН3 ОН	methyl-phenoxy)-acetic
59	0 0	acid (4-{2-[(3'-Fluoro-
	S N S CH <sub>3</sub>	biphenyl-4-sulfonyl)- propyl-amino]-
	CH. OH	ethylsulfanyl}-2-
	CH₃ OH	methyl-phenoxy)-acetic acid
60	O CH <sub>3</sub>	(4-{2-[(2'-Chloro-biphenyl-4-sulfonyl)-
		Diplicity1-4-SulfOlly1/-
		propyl-amino]-
	CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2-
61	3	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
61	CH <sub>3</sub> ON S CH <sub>3</sub> CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)-
61	OSI NO SCH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]-
61	3	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic
61	CI CH <sub>3</sub> CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy-
	OSI NO SCH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
	CI CH <sub>3</sub> CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2-
62	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(3'-Chloro-4'-
62	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH  CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(3'-Chloro-4'- fluoro-biphenyl-4- sulfonyl)-propyl-
62	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(3'-Chloro-4'- fluoro-biphenyl-4-

64	F F O O S N S CH <sub>3</sub> CH <sub>3</sub> O O O O O O O O	(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
65	Chiral CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH	(2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
66	H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub> OH	(2-Methyl-4-{1-methyl-2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
67	F F O O Chiral  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
68	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH	(4-{2-[(3-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
69	H <sub>3</sub> C OH <sub>3</sub> OH	(4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid
70	H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub> OH	(4-{2-[(4-Isobutyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid

71	1.1	(4 (0 f(0 G))
71	CI O chiral	(4-{2-[(2-Chloro-4-
	S CH <sub>3</sub>	trifluoromethyl-
	F	benzenesulfonyl)-
	CH <sub>3</sub> CH <sub>3</sub> O	propyl-amino]-1-
		methyl-ethylsulfanyl}-
	F CH₃ OH	2-methyl-phenoxy)-
		acetic acid
72	O chiral	(4-{2-[(4-Bromo-3-
	CI S CH <sub>3</sub>	chloro-
		benzenesulfonyl)-
	Br CH <sub>3</sub>	propyl-amino]-1-
		methyl-ethylsulfanyl}-
	CH <sub>3</sub> OH	2-methyl-phenoxy)-
		acetic acid
73	o chiral	(4-{2-[(4-Butyl-3-
	CI S CH <sub>3</sub>	chloro-
	H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub>	benzenesulfonyl)-
	H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub>	propyl-amino]-1-
	Сн₃ он	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
74	O chiral	(4-{2-[(3-Chloro-4-
	S S S C C C C C C C C C C C C C C C C C	isobutyl-
	CH <sub>3</sub>	benzenesulfonyl)-
	H <sub>3</sub> C CH <sub>3</sub> O O	propyl-amino]-1-
	сн <sub>з</sub> он	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
75	O chiral	(4-{2-[(4-Bromo-
	S CH <sub>3</sub>	benzenesulfonyl)-
		propyl-amino]-1-
	CH <sub>3</sub>	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
	ĊH <sub>3</sub> OH	acetic acid
76	O chiral	(4-{2-[(4-Butyl-
	S CH <sub>3</sub>	benzenesulfonyl)-
	H <sub>3</sub> C CH <sub>3</sub> CO	propyl-amino]-1-
	H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub>	methyl-ethylsulfanyl}-
	с́н₃ о́н	2-methyl-phenoxy)-
		acetic acid
77	O chiral	(4-{2-[(2-Chloro-4'-
	O II S CH <sub>3</sub>	fluoro-biphenyl-4-
		sulfonyl)-propyl-
	CH, CH,	amino]-1-methyl-
		ethylsulfanyl}-2-
	CH <sub>3</sub> OH	methyl-phenoxy)-acetic
		acid

78	O chiral	(4 12 1/2 Chlora 4
/ 6	0. 11	(4-{2-[(3-Chloro-4-
		propyl-
	CH <sub>3</sub>	benzenesulfonyl)-
	H <sub>3</sub> C O	propyl-amino]-1-
	ĊH₃ ÓH	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
70		acetic acid
79	CH₃	(4-{2-[(5-Chloro-3-
	CH ~ )	methyl-
	CI CH <sub>3</sub> O S OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	s o	amino]-ethylsulfanyl}-
	СН <sub>3</sub>	2-propyl-phenoxy)-
		acetic acid
80	CI CH <sub>3</sub> O O	(4-{2-[(5-Chloro-3-
	S S S S S S S S S S S S S S S S S S S	methyl-
	S N S OH	benzo[b]thiophene-2-
e e		sulfonyl)-propyl-
	CH <sub>3</sub>	amino]-ethylsulfanyl}-
<u></u>		phenoxy)-acetic acid
81	F <sub>F</sub> F	(4-{2-[(5-Chloro-3-
	·	methyl-
	CH <sub>3</sub> O S-OOO	benzo[b]thiophene-2-
	S-N OH	sulfonyl)-propyl-
	s' ö'	amino]-ethylsulfanyl}-
		2-trifluoromethyl-
	CH <sub>3</sub>	phenoxy)-acetic acid
82	F <sup>+</sup> F ÇH₃ ÇH₃ Ω	[2-Methyl-4-(1-
	CH. L' O. L	{[propyl-(4-
	OH CHIEF	trifluoromethoxy-
	$\left  \begin{array}{c} \left  \left  \left  \right  \right  \right  \\ \left  \left  \right  \right  \right  \\ \left  \left  \right  \right  \right  \right $	benzenesulfonyl)-
	0.0	amino]-methyl}-
		propylsulfanyl)-
		phenoxy]-acetic acid
83	CH₃	(4-{2-[(5-Chloro-3-
	ÇH₃ s—⟨¯⟩—о о	methyl-
	CH <sub>3</sub> OCH OH	benzo[b]thiophene-2-
	_ S-N CH₃ OH	sulfonyl)-propyl-
	~ ° ° /	amino]-1-methyl-
	CH <sub>3</sub>	ethylsulfanyl}-2-
	,	methyl-phenoxy)-acetic
0.4	OH.	acid
84	CH₃	(4-{2-[(5-Chloro-3-
	CH <sub>3</sub> O CH <sub>3</sub> O OH	methyl-
		benzo[b]thiophene-2-
]	Ĺ ∭ Ņ—ÿ-n( ˙CH₃ ˙OH	sulfonyl)-propyl-
	✓ 'S Ö 〉	amino]-1-methyl-
	CH	ethylsulfanyl}-2-
	CH <sub>3</sub>	methyl-phenoxy)-acetic
L		acid

85	F CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	(2-Methyl-4-{2-[(3-methyl-5-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid (2-Methyl-4-{2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
87	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OOO OOO OOO	(4-{2-[(4-Ethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
88	OH OH CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	(2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
89	FFF O O O O O O O O O O O O O O O O O O	(2-Methyl-4-{2-[propyl- (4-trifluoromethoxy- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
90	CH <sub>3</sub> OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

91	ÇH₃	(4 (2 )(5 Chlass 2
91		(4-{2-[(5-Chloro-3-
	CH₃ S—( )—O, O	methyl-
		benzo[b]thiophene-2-
		sulfonyl)-(3-methyl-
	\ \sigma  \qq	butyl)-amino]-
	├─CH₃	ethylsulfanyl}-2-
	Н <sub>3</sub> С	methyl-phenoxy)-acetic
-		acid
92	CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
		methyl-
	Ch CH <sub>3</sub> S—O O	benzo[b]thiophene-2-
	CI SI-N OH	sulfonyl)-cyclopropyl-
	s ii ii	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
93	,CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
		methyl-
	CH <sub>3</sub> S-\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	benzo[b]thiophene-2-
	CI SHOW OH	sulfonyl)-cyclobutyl-
	OH OH	amino]-ethylsulfanyl}-
	1 7 7	2-methyl-phenoxy)-
	7	acetic acid
94	,CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
		methyl-
	CH₃ S—⟨ >—O O	benzo[b]thiophene-2-
		sulfonyl)-
	CI OH OH	cyclopropylmethyl-
		amino]-ethylsulfanyl}-
		2-methyl-phenoxy)- acetic acid
95	,CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
/3	· /=<	methyl-
	CH <sub>3</sub> S-\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	1 •
		benzo[b]thiophene-2-
	S O OH	sulfonyl)-pentyl-amino]-
		ethylsulfanyl}-2-
	<b>&gt;</b>	methyl-phenoxy)-acetic
	\ 	acid
06	ČH <sub>3</sub>	
96	CH <sub>3</sub>	(4-{2-[Butyl-(5-chloro-
	CH3 S-(-)-O O	3-methyl-
1	CH <sub>3</sub> O S OH	benzo[b]thiophene-2-
	S-N OH	sulfonyl)-amino]-
	s ö >	ethylsulfanyl}-2-
	<b>\</b>	methyl-phenoxy)-acetic
	н <sub>з</sub> с	acid
	1130	

97	CH <sub>3</sub>	(4-{2-[(Biphenyl-4-
		sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
	`s-(	2-methyl-phenoxy)-
		acetic acid
	ОН	
98	CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
	CH <sub>3</sub> O————————————————————————————————————	methyl-
		benzo[b]thiophene-2-
1	ÿ-ÿ-n OH	sulfonyl)-propyl-
	" " 0 /	amino]-ethoxy}-2-
	CH <sub>3</sub>	methyl-phenylsulfanyl)-
		acetic acid
99	CH <sub>3</sub>	(4-{3-[(5-Chloro-3-
	Сн <sub>3</sub> ————————————————————————————————————	methyl-
		benzo[b]thiophene-2-
	CH <sub>3</sub> OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	sulfonyl)-propyl-
		amino]-propyl}-2-
	CH <sub>3</sub>	methyl-phenoxy)-acetic
100		acid
100	CH₃	(4-{2-[(5-Chloro-3-
	СН <sub>3</sub> О— ДО О	methyl-
		benzo[b]thiophene-2-
		sulfonyl)-propyl-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	amino]-1-methyl-
	CH <sub>3</sub>	ethoxy}-2-methyl-
101	,CH <sub>3</sub>	phenoxy)-acetic acid
101	Cn <sub>3</sub>	3-(4-{2-[(5-Chloro-3-
	CH <sub>3</sub> O CH <sub>3</sub> O OH	methyl-
		benzo[b]thiophene-2-
	Г Г У Ё-и́ Сн₃ Он	sulfonyl)-propyl-
		amino]-1-methyl-
	CH <sub>3</sub>	ethoxy}-2-methyl-
100		phenyl)-propionic acid
102	CH₃	2-(4-{2-[(5-Chloro-3-
	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	methyl-
	CI S N CH <sub>3</sub> H <sub>3</sub> C OH	benzo[b]thiophene-2-
	Ę Į "— į į · i · ch <sub>3</sub> · i · i · i · i · i · i · i · i · i ·	sulfonyl)-propyl-
	° S Ö ⟩	amino]-1-methyl-
	( ,	ethoxy}-2-methyl-
	CH₃	phenoxy)-2-methyl-
102	0.011	propionic acid
103	O-CH <sub>3</sub>	3-(4-{2-[(5-Chloro-3-
	CH3 O— O	methyl-
		benzo[b]thiophene-2-
	□ S N CH₃ OH	sulfonyl)-propyl-
	~ * 0 /	amino]-1-methyl-
	С Н <sub>з</sub>	ethoxy}-2-methoxy-
L		phenyl)-propionic acid

104	CH₃	(4-{2-[(5-Fluoro-3-
	/ <del>_</del>	methyl-
	F CH <sub>3</sub> O S O	benzo[b]thiophene-2-
	│	sulfonyl)-propyl-
	s ö	amino]-1-methyl-
	CH <sub>3</sub>	ethylsulfanyl}-2-
	511 <sub>3</sub>	methyl-phenoxy)-acetic
105	CH <sub>3</sub>	acid
103		3-(4-{2-[(5-Fluoro-3-methyl-
	F S N CH <sub>3</sub> OH	benzo[b]thiophene-2-
	- S-N CH3 OH	sulfonyl)-propyl-
	S OH	amino]-1-methyl-
		ethoxy}-2-methyl-
	CH₃	phenyl)-propionic acid
106	,CH₃	(4-{2-[(5-Fluoro-3-
	F CH <sub>3</sub> O CH <sub>3</sub> OH	methyl-
	F, CH <sub>3</sub> O O O	benzo[b]thiophene-2-
	[ ] → ;;-n CH₃ OH	sulfonyl)-propyl-
	s ö	amino]-1-methyl-
	CH₃	ethoxy}-2-methyl-
107		phenoxy)-acetic acid
107	ÇI	(2-Chloro-4-{2-[(5-
	CI CH <sub>3</sub> O OH	chloro-3-methyl- benzo[b]thiophene-2-
		sulfonyl)-propyl-
	S OH	amino]-ethylsulfanyl}-
		phenoxy)-acetic acid
	СН <sub>3</sub>	
108	CH <sub>3</sub> CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
		methyl-
	S CH <sub>3</sub>	benzo[b]thiophene-2-
	`s-{\_}-\	sulfonyl)-propyl-
	_ ~	amino]-ethylsulfanyl}-
	ОН	2-ethyl-phenoxy)-acetic
109	OH	acid (2-Methyl-4-{2-
10	O= CH₃	[(naphthalene-2-
	_O	sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
		phenoxy)-acetic acid
	O'S'	
	o.s	
	<b>(</b> )	
		.
Ll		

110	H <sub>3</sub> C O S F N S O CH <sub>3</sub> H <sub>3</sub> C O CH <sub>3</sub>	(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
111	F O S CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	[3-Chloro-4-(1- {[propyl-(4- trifluoromethoxy- benzenesulfonyl)- amino]-methyl}- propylsulfanyl)-phenyl]- acetic acid
112	CI CH <sub>3</sub> O Chiral Chiral CH <sub>3</sub> O OH CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	(R)-(3-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-phenyl)-acetic acid
113	CI CH <sub>a</sub> S HO  CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	(3-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenyl)-acetic acid
114	CH <sub>3</sub> O OH OH	[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid
115	CH <sub>3</sub> OH S N OH CH <sub>3</sub> C CH <sub>3</sub>	3-[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid

116	CH <sub>3</sub> CH <sub>3</sub> O OH  CH <sub>3</sub> CH <sub>3</sub> OH  CH <sub>3</sub> OH	3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-butoxy}-2-methyl-phenyl)-propionic acid
117	CH <sub>3</sub> CH <sub>3</sub> O OH	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid
118	CI CH <sub>3</sub> O,S,N O,S,N OH OH	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methoxy-phenoxy]-acetic acid
119	CH <sub>3</sub> CH <sub>3</sub> O OH	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-phenethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
120	CH <sub>3</sub> OH OH	(4-{2-[Benzyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
121	CH <sub>3</sub> CH <sub>3</sub> O O O CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid

- 25. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claims 1 24Claim 1 or pharmaceutically acceptable salts, solvates or hydrates thereof.
- 26. (Currently Amended) A pharmaceutical composition comprising (1) a compound of Claim 1–24Claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof; (2) a second therapeutic agent selected from the group consisting of insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and (3) a pharmaceutically acceptable carrier.
- 27. (Currently Amended) A method of modulating a peroxisome proliferator activated receptor (PPAR), comprising the step of contacting the receptor with at least one compound of Claims 1-24Claim 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 28. (Original) The method of Claim 27, wherein the PPAR is a gamma receptor.
- 29. (Original) The method of Claim 27, wherein the PPAR is a delta-receptor.
- 30. (Original) The method of Claim 27, wherein the PPAR is a gamma and delta-receptor.
- 31. (Currently Amended) A method for treating or preventing a PPAR-gamma mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1 24Claim 1.

- 32. (Currently Amended) A method for treating or preventing a PPAR-delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1 24Claim 1.
- 33. (Currently Amended) A method for treating or preventing a PPAR-gamma and delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1 24Claim 1.
- 34. (Currently Amended) A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24Claim 1.
- 35. (Currently Amended) A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1 24Claim 1.
- 36. (Currently Amended) A method of treating or preventing diabetes mellitus in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1 24Claim 1.
- 37. (Currently Amended) A method of treating or preventing cardiovascular disease in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24Claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
- 38. (Currently Amended) A method of treating or preventing syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-24Claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

- 39. (Currently Amended) A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24Claim 1 and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.
  - 40. (Cancelled)